Charles Schwab Investment Management Inc. Lowers Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Charles Schwab Investment Management Inc. cut its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 65.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 70,946 shares of the company’s stock after selling 137,192 shares during the period. Charles Schwab Investment Management Inc.’s holdings in RAPT Therapeutics were worth $143,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in RAPT. Federated Hermes Inc. increased its stake in RAPT Therapeutics by 188.7% in the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock valued at $2,428,000 after purchasing an additional 520,368 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in RAPT Therapeutics by 176,725.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after buying an additional 706,900 shares during the period. Acadian Asset Management LLC increased its stake in shares of RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after acquiring an additional 456,275 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of RAPT Therapeutics by 826.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock worth $900,000 after acquiring an additional 263,372 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of RAPT Therapeutics by 108.1% in the second quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock worth $622,000 after acquiring an additional 105,900 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $0.81 on Friday. The business’s 50-day moving average is $1.53 and its two-hundred day moving average is $2.27. The firm has a market capitalization of $28.24 million, a PE ratio of -0.29 and a beta of 0.07. RAPT Therapeutics, Inc. has a 12 month low of $0.79 and a 12 month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Equities analysts anticipate that RAPT Therapeutics, Inc. will post -2.86 EPS for the current year.

Analysts Set New Price Targets

RAPT has been the subject of several research analyst reports. Wells Fargo & Company dropped their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Monday, November 25th. UBS Group cut their target price on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.50.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.